Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framewo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rassy, Elie, Andre, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546809/
https://www.ncbi.nlm.nih.gov/pubmed/37665780
http://dx.doi.org/10.1093/oncolo/oyad248
_version_ 1785114936546951168
author Rassy, Elie
Andre, Fabrice
author_facet Rassy, Elie
Andre, Fabrice
author_sort Rassy, Elie
collection PubMed
description This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framework of this approach is based on the integration of basic biology, biotechnologies, data sciences, clinical research, and social sciences.
format Online
Article
Text
id pubmed-10546809
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105468092023-10-04 Can Precision Oncology Benefit Patients With Cancers of Unknown Primary? Rassy, Elie Andre, Fabrice Oncologist Editorial This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framework of this approach is based on the integration of basic biology, biotechnologies, data sciences, clinical research, and social sciences. Oxford University Press 2023-09-04 /pmc/articles/PMC10546809/ /pubmed/37665780 http://dx.doi.org/10.1093/oncolo/oyad248 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Rassy, Elie
Andre, Fabrice
Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title_full Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title_fullStr Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title_full_unstemmed Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title_short Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
title_sort can precision oncology benefit patients with cancers of unknown primary?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546809/
https://www.ncbi.nlm.nih.gov/pubmed/37665780
http://dx.doi.org/10.1093/oncolo/oyad248
work_keys_str_mv AT rassyelie canprecisiononcologybenefitpatientswithcancersofunknownprimary
AT andrefabrice canprecisiononcologybenefitpatientswithcancersofunknownprimary

Ejemplares similares